FABHALTA (iptacopan), FDA Approved for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria, Available at Biologics by McKesson

CARY, N.C., Dec. 20, 2023 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by Novartis as a specialty pharmacy provider for FABHALTA® (iptacopan). FABHALTA, approved by the U.S. Food and Drug Administration (FDA) on Dec. 5, 2023, is ...
Source: McKesson News - Category: Information Technology Source Type: news